RLMD

Business Context and Reporting Period

Company: Relmada Therapeutics, Inc. (RLMD)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Relmada is a clinical-stage biotechnology company that substantially redesigned its development strategy in late 2024 following the failure of its lead candidate, esmethadone (REL-1017), in a Phase 3 trial for Major Depressive Disorder (MDD). The company has paused the REL-1017 and psilocybin (REL-P11) programs. The new strategy focuses on acquiring and developing new candidates: Sepranolone (neurosteroid for Prader-Willi Syndrome and Tourette Syndrome) and NDV-01 (bladder cancer therapy).

Key Financial Metrics

Material Changes vs. Prior Period

• Strategic Pivot: The company paused its primary drug candidate (esmethadone) after a Phase 3 interim analysis indicated futility. It also paused its psilocybin program.
• Expense Reduction: Total operating expenses decreased by approximately $19.8 million year-over-year. R&D expenses dropped $8.6 million primarily due to the completion of Phase 3 trials in 2023. G&A expenses dropped $11.2 million, largely driven by a $12.3 million decrease in stock-based compensation as prior equity grants vested and new grants were limited.
• Liquidity Position: Total liquidity (cash and short-term investments) decreased significantly from ~$96.3 million in 2023 to ~$44.9 million in 2024, primarily due to the sale of short-term investments to fund operations.
• Subsequent Transactions: Post-year-end, the company acquired Sepranolone (Feb 2025) and in-licensed NDV-01 (March 2025), involving cash payments and the issuance of 3,017,420 shares of common stock (10% of outstanding shares) for the NDV-01 deal.

Guidance, Outlook, Risks, and Contingencies

• Going Concern Warning: The company has raised substantial doubt about its ability to continue as a going concern. Management projects insufficient liquidity to sustain operations for one year following the issuance of the financial statements.
• Capital Needs: The company expects to incur additional losses and requires significant additional funding to advance its new pipeline (Sepranolone and NDV-01). Financing strategies may include equity or debt sales, but there is no assurance of availability or favorable terms.
• Nasdaq Compliance: The company received a deficiency letter from Nasdaq on January 21, 2025, for failing to maintain the $1.00 minimum bid price requirement. It has 180 days (until July 21, 2025) to regain compliance or face delisting.
• Key Milestones:
  • NDV-01 Phase 2a data presentation (1st Half 2025).
  • NDV-01 US Investigational New Drug clearance (2nd Half 2025).
  • Sepranolone clinical trial initiation in Prader-Willi Syndrome (Year-end 2025).
• Risks: Risks include the failure of new drug candidates, inability to secure financing, potential delisting from Nasdaq, and the "Key Man" provision in the esmethadone license agreement which restricts the termination of the CEO until December 2027.

Investor Verification Checklist

• Liquidity Runway: Verify the current cash burn rate and the timeline for the next capital raise given the "Going Concern" warning.
• Nasdaq Status: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement before July 21, 2025, to avoid delisting.
• Dilution Impact: Assess the impact of the 3,017,420 shares issued for the NDV-01 license (10% of outstanding shares) on existing shareholder value.
• Pipeline Viability: Review the Phase 2a data for NDV-01 and the clinical strategy for Sepranolone, as the company has no approved products and no revenue.
• CEO Tenure: Note the contractual restriction preventing the termination of CEO Sergio Traversa without cause until December 31, 2027.